Dr. Mali's Top 5 Predictions in Ophthalmology for 2022

Mar 21, 2022

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

• Welcome to another exciting episode of Eye Care insider :50
• My top 5 predictions for 2022 1:16
• Prediction #1 – on COVID-19 1:27
• Prediction #2 – on wet AMD 2:43
• Prediction #3 – on ocular gene therapy 4:05
• Prediction #4 – on geographic atrophy 5:05
• Prediction #5 – on ophthalmology media platforms 7:23
• Thanks for listening 9:20

We’d love to hear from you! Send your comments/questions to Dr. Mali at [e-mail]. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.